Brief: Neurocrine Biosciences Q3 Adjusted EPS USD 1.81 Vs. IBES Estimate USD 1.51
30/10/2024 11:01
Oct 30 (Reuters) - Neurocrine Biosciences Q3 product sales USD 616.6 million. * Q3 EPS USD 1.24 * Q3 adjusted net income USD 189.2 million vs. IBES estimate USD 154.3 million * Q3 net income USD 129.8 million
Recent news on Neurocrine Biosciences
See all newsBrief: Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating Nbi-'567 In Adults With Alzheimer's Disease
Nxera Pharma's Partner Neurocrine Biosciences Receives Ind Acceptance From FDA For Phase 2 Study Of Nbi-1117567 For Alzheimer's Cognition
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Prader-Willi groups cite deaths tied to Neurocrine's genetic disorder drug, shares fall